MAIN CONTENT
A large deal for an early-stage program
Genentech, a member of the Roche Group, has obtained exclusive worldwide rights to develop, manufacture and commercialize AL050. Alector will receive $100 million upfront and could earn up to another $1.17 billion if the program reaches specified development, regulatory and sales milestones. It is also eligible for tiered royalties on net sales if the therapy eventually reaches the market.
The scale of the potential package reflects growing interest in disease-modifying approaches to neurodegeneration, but most of the $1.27 billion figure is contingent. For Alector, the upfront payment is the most certain part of the economics today; the rest depends on a long sequence of scientific, clinical and commercial successes.
AL050 targets GCase and the blood-brain barrier problem
GCase, short for glucocerebrosidase, is an enzyme involved in breaking down certain lipids inside cells. In people with GBA1 mutations, GCase activity can be reduced, allowing glucosylceramide and glucosylsphingosine to accumulate in neurons. GBA1 is among the most important genetic risk factors associated with Parkinson’s disease and Lewy body dementia, making GCase a compelling therapeutic target.

















